Therapy News and Research

RSS

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.

16 Dec 2013

Robotic trolley system helps overcome falling fear for patients who recovering from stroke, brain injury

The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.

16 Dec 2013

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression, according to the results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

CHOP scientist receives 2013 E. Donnall Thomas Prize for scientific, clinical research in hemophilia

Katherine A. High, M.D., of The Children's Hospital of Philadelphia (CHOP) was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology (ASH) at its annual meeting on Dec. 9 in New Orleans.

15 Dec 2013

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

A Massachusetts General Hospital research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men. In the Dec. 1 issue of the Journal of Infectious Diseases the investigators report finding that HIV-infected women had a greater prevalence of the type of coronary artery plaque most vulnerable to rupture than did uninfected women.

14 Dec 2013

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

14 Dec 2013

CHOP scientist receives 2013 E. Donnall Thomas Prize for research in bleeding disorder hemophilia

Katherine A. High, M.D., of The Children's Hospital of Philadelphia was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology at its annual meeting on Dec. 9 in New Orleans.

14 Dec 2013

MD Anderson researcher earns Breakthrough Prize in Life Sciences

Basic science research that exposed vital details of cancer's defense against the immune system, revealing an entirely new way to combat these diseases, has earned Jim Allison, Ph.D., a Breakthrough Prize in Life Sciences.

14 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.

13 Dec 2013

Specialists use pioneering treatment to reduce high blood pressure in kidney patient

SPECIALISTS at Sheffield Teaching Hospitals NHS Foundation Trust have used a pioneering treatment to reduce high blood pressure in a kidney patient whose blood pressure could not be controlled with conventional medication.

13 Dec 2013

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients.

13 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

Psychology researchers and practitioners still hold different beliefs about repressed memories

Skepticism about repressed traumatic memories has increased over time, but new research shows that psychology researchers and practitioners still tend to hold different beliefs about whether such memories occur and whether they can be accurately retrieved.

13 Dec 2013

New mutations in the estrogen receptor drive strong drug resistance exhibited by human breast tumors

Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research from Washington University School of Medicine in St. Louis.

13 Dec 2013

Genomic tests help in selecting the most effective therapy for breast cancer

Genomic tests that determine the molecular subtype of a woman's breast cancer provide a more precise prognosis and valuable guidance about the best treatment, according to new research led by Massimo Cristofanilli, M.D, Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals.

13 Dec 2013

Therapy News and Research

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Robotic trolley system helps overcome falling fear for patients who recovering from stroke, brain injury

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Study could lead towards a personalised medicine for chemoresistant lymphomata

CHOP scientist receives 2013 E. Donnall Thomas Prize for scientific, clinical research in hemophilia

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

CHOP scientist receives 2013 E. Donnall Thomas Prize for research in bleeding disorder hemophilia

MD Anderson researcher earns Breakthrough Prize in Life Sciences

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

Cetuximab fails in second-line combination for recurrent NSCLC

Specialists use pioneering treatment to reduce high blood pressure in kidney patient

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

Psychology researchers and practitioners still hold different beliefs about repressed memories

New mutations in the estrogen receptor drive strong drug resistance exhibited by human breast tumors

Genomic tests help in selecting the most effective therapy for breast cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News